Talk:Beta blocker: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 03:22, 18 October 2017 editBiochemistry&Love (talk \| contribs)Extended confirmed users, New page reviewers5,950 edits →Unsourced: Cited.← Previous edit		Latest revision as of 16:33, 3 November 2024 edit undo2607:fea8:3d1d:d000:2a:b577:3a3:f39 (talk)No edit summaryTags: Mobile edit Mobile web edit New topic
(34 intermediate revisions by 10 users not shown)
Line 1:		Line 1:
		⚫	{{Talk header}}
		⚫	{{WikiProject banner shell\|class=C\|
			{{WikiProject Pharmacology\|importance=top}}
			}}
		⚫	{{Reliable sources for medical articles}}
	{{User:MiszaBot/config		{{User:MiszaBot/config
	\|archiveheader = {{aan}}		\|archiveheader = {{aan}}
	\|maxarchivesize = 200K		\|maxarchivesize = 200K
	\|counter = 0		\|counter = 1
	\|minthreadsleft = 0		\|minthreadsleft = 0
	\|minthreadstoarchive = 1		\|minthreadstoarchive = 1
Line 8:		Line 13:
	\|archive = Talk:Beta blocker/Archive %(counter)d		\|archive = Talk:Beta blocker/Archive %(counter)d
	}}		}}
			{{Connected contributor (paid)\|User1=Cglife.trummler\|U1-employer=CG Life\|U1-client=Impact Journals}}.
⚫	{{Reliable sources for medical articles}}
⚫	{{~~talk~~ header}}
⚫	{{WikiProject ~~Pharmacology~~\|class=C\|~~importance=top}}~~


	== Unsourced ==

	Moved here per ] as this is almost all unsourced. Per ] please do not restore without finding reliable sources, checking the content against them, and citing the sources.

	;Examples
	], the first beta
	blocker]]

	;Nonselective agents
	*]<ref name="PharmLetter BB Table">{{cite web\|title=Comparison of Oral Beta-Blockers\|url=https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2012/Dec/Comparison-of-Oral-Beta-Blockers-5052\|website=pharmacist.therapeuticresearch.com\|publisher=Therapeutic Research Center\|accessdate=30 April 2017}}</ref>
	*] (has additional α1-blocking activity)<ref>{{cite journal \|vauthors=Rosendorff C \|title=Beta-blocking agents with vasodilator activity \|journal=Journal of Hypertension. Supplement \|volume=11 \|issue=4 \|pages=S37–40 \|year=1993 \|pmid=8104240 \|doi=10.1097/00004872-199306003-00009}}</ref>
	*]<ref>{{cite web\|title=CARTEOLOL\|url=https://pubchem.ncbi.nlm.nih.gov/compound/carteolol\|website=pubchem.ncbi.nlm.nih.gov\|publisher=U.S. National Library of Medicine\|accessdate=18 October 2017\|language=en}}</ref>
	*] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" />
	*] (has additional α1-blocking activity)<ref name="PharmLetter BB Table" />
	*]<ref name="PharmLetter BB Table" />
	*] (has intrinsic sympathomimetic activity)<ref name="oxprenolol">{{cite web\|title=oxprenolol\|url=https://pubchem.ncbi.nlm.nih.gov/compound/4631\|website=pubchem.ncbi.nlm.nih.gov\|publisher=U.S. National Library of Medicine\|accessdate=18 October 2017\|language=en}}</ref>
	*] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" />
	*] (has intrinsic sympathomimetic activity)<ref name="PharmLetter BB Table" />
	*] (not considered a "typical beta-blocker")<ref name="PharmLetter BB Table" />
	*]<ref name="PharmLetter BB Table" />

	;β<sub>1</sub>-selective agents
	Also known as cardioselective
	*] (has intrinsic sympathomimetic activity, ISA)<ref name="PharmLetter BB Table" />
	*]<ref name="PharmLetter BB Table" />
	*]<ref name="PharmLetter BB Table" />
	*]<ref name="PharmLetter BB Table" />
	*] (has intrinsic sympathomimetic activity)<ref name"Celiprolol">{{cite web\|title=Celiprolol\|url=https://pubchem.ncbi.nlm.nih.gov/compound/2663\|website=pubchem.ncbi.nlm.nih.gov\|publisher=U.S. National Library of Medicine\|accessdate=18 October 2017\|language=en}}</ref>
	*]<ref name="PharmLetter BB Table" />
	*]<ref name="PharmLetter BB Table" />

	;β<sub>2</sub>-selective agents
	*]<ref>{{cite web\|title=Butaxamine\|url=https://pubchem.ncbi.nlm.nih.gov/compound/18026\|website=pubchem.ncbi.nlm.nih.gov\|publisher=U.S. National Library of Medicine\|accessdate=18 October 2017\|language=en}}</ref>
	*]<ref>{{cite web\|title=ICI 118551 hydrochloride\|url=http://www.abcam.com/ici-118551-hydrochloride-ab120808.html\|website=abcam.com\|publisher=Abcam plc\|accessdate=18 October 2017\|language=en}}</ref>

	;β<sub>3</sub>-selective agents
	*]<ref>{{cite web\|title=SR 59230A\|url=https://pubchem.ncbi.nlm.nih.gov/compound/9888075\|website=pubchem.ncbi.nlm.nih.gov\|publisher=U.S. National Library of Medicine\|accessdate=18 October 2017\|language=en}}</ref>

			== Hyperthyroidism ==
	;Comparative information

			I removed hyperthyroidism from the list of contraindications because the source doesn't list it as a contraindication for beta blockers; it says that it can exacerbate hyperthyroid symptoms if discontinued abruptly. Hyperthyroidism is also listed as an ''indication'' for beta blockers earlier in the article, so it's contradicting itself.
	;Pharmacological differences
	*Agents with intrinsic sympathomimetic action (ISA)
	**Acebutolol,<ref name="BB in HTN Meta-analyses">{{cite journal\|last1=Larochelle\|first1=Pierre\|last2=Tobe\|first2=Sheldon W.\|last3=Lacourcière\|first3=Yves\|title=β-Blockers in Hypertension: Studies and Meta-analyses Over the Years\|journal=Canadian Journal of Cardiology\|date=May 2014\|volume=30\|issue=5\|pages=S16–S22\|doi=10.1016/j.cjca.2014.02.012\|accessdate=18 October 2017}}</ref> pindolol,<ref name="BB in HTN Meta-analyses" /> labetalol,<ref name="BB in HTN Meta-analyses" /> celiprolol,<ref name"Celiprolol" /> mepindolol,<ref>{{cite book\|last1=Mulrow\|first1=edited by Detlev Ganten, Patrick J.\|title=Pharmacology of Antihypertensive Therapeutics\|date=1990\|publisher=Springer Berlin Heidelberg\|location=Berlin, Heidelberg\|isbn=9783642742095\|page=523\|accessdate=18 October 2017}}</ref> oxprenolol<ref name="oxprenolol" />
	*Agents organized by lipid solubility (lipophilicity)<ref>{{cite journal\|last1=Zipursky\|first1=Jonathan S.\|last2=Macdonald\|first2=Erin M.\|last3=Luo\|first3=Jin\|last4=Gomes\|first4=Tara\|last5=Mamdani\|first5=Muhammad M.\|last6=Paterson\|first6=J. Michael\|last7=Juurlink\|first7=David N.\|title=Lipophilic β-Blockers and Suicide in the Elderly\|journal=Journal of Clinical Psychopharmacology\|date=June 2017\|volume=37\|issue=3\|pages=381–384\|doi=10.1097/JCP.0000000000000695\|url=https://insights.ovid.com/pubmed?pmid=28338548\|accessdate=18 October 2017}}</ref>
	**High lipophilicity: propranolol, labetalol
	**Intermediate lipophilicity: metoprolol, bisoprolol, carvedilol, acebutolol, timolol, pindolol
	**Low lipophilicity (also known as hydrophilic beta-blockers): atenolol, nadolol, and sotalol
	*Agents with ]
	**Acebutolol, ]

			I also removed the sentence claiming that beta blockers should be used with caution because "tachycardia is a useful monitoring parameter in thyroid disease" because it was uncited and I doubt it's possible to find a citation for this. I'm not sure what kind of doctor would be ok with not treating a patient's abnormally high heart rate because it's a (not very precise) indicator that their thyroid levels are abnormal.
	;Indication differences
	*Agents specifically labeled for cardiac arrhythmia
	**], ], ]
	*Agents specifically labeled for congestive heart failure
	**], ], ],
	*Agents specifically labeled for glaucoma
	**], ], ], ], ]
	*Agents specifically labeled for myocardial infarction
	**], ], ]
	*Agents specifically labeled for migraine prophylaxis<ref name="PL Chart Migraine">{{cite web\|title=Drugs to Prevent Migraine in Adults\|url=https://pharmacist.therapeuticresearch.com/Content/Segments/PRL/2012/Jul/Drugs-to-Prevent-Migraine-in-Adults-4513\|website=pharmacist.therapeuticresearch.com\|publisher=Therapeutic Research Center\|accessdate=30 April 2017}}</ref>
	**], ]

			I left the line about abrupt withdrawal possibly causing a thyroid storm because that is in the propanolol document (and added the citation that wasn't there), but it doesn't contraindicate the use of beta blockers to treat hyperthyroidism and shouldn't be in that section. I'm just not sure how to fit it into the Adverse Effects section smoothly. I'm also not sure if it should even be included in the article, since I assume hyperthyroidism is not the only condition for which suddenly stopping beta blockers can be potentially dangerous, but it's the only disorder for which it's mentioned. (And if we're being pedantic, that citation is only for propanolol and not for other beta blockers.)
	] is the only agent indicated for control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in ].<ref name="Rossi"/>

			Heyvgy ] (]) 16:33, 3 November 2024 (UTC)
	{{reflist-talk}}

Latest revision as of 16:33, 3 November 2024

This is the talk page for discussing improvements to the Beta blocker article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Misplaced Pages? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Archives: 1Auto-archiving period: 2 months

This article is rated C-class on Misplaced Pages's content assessment scale.
It is of interest to the following WikiProjects:

Pharmacology Top‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Misplaced Pages. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Top	This article has been rated as Top-importance on the project's importance scale.

Ideal sources for Misplaced Pages's health content are defined in the guideline Misplaced Pages:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Beta blocker.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.

Cglife.trummler (talk · contribs) has been paid by CG Life on behalf of Impact Journals.

Hyperthyroidism

I removed hyperthyroidism from the list of contraindications because the source doesn't list it as a contraindication for beta blockers; it says that it can exacerbate hyperthyroid symptoms if discontinued abruptly. Hyperthyroidism is also listed as an indication for beta blockers earlier in the article, so it's contradicting itself.

I also removed the sentence claiming that beta blockers should be used with caution because "tachycardia is a useful monitoring parameter in thyroid disease" because it was uncited and I doubt it's possible to find a citation for this. I'm not sure what kind of doctor would be ok with not treating a patient's abnormally high heart rate because it's a (not very precise) indicator that their thyroid levels are abnormal.

I left the line about abrupt withdrawal possibly causing a thyroid storm because that is in the propanolol document (and added the citation that wasn't there), but it doesn't contraindicate the use of beta blockers to treat hyperthyroidism and shouldn't be in that section. I'm just not sure how to fit it into the Adverse Effects section smoothly. I'm also not sure if it should even be included in the article, since I assume hyperthyroidism is not the only condition for which suddenly stopping beta blockers can be potentially dangerous, but it's the only disorder for which it's mentioned. (And if we're being pedantic, that citation is only for propanolol and not for other beta blockers.)

Heyvgy 2607:FEA8:3D1D:D000:2A:B577:3A3:F39 (talk) 16:33, 3 November 2024 (UTC)

Categories: